मूलभूत आँकड़े
| LEI | 549300NTYWN4CVYSCN32 |
| CIK | 1833141 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cybin Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 4, 2025 |
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference TORONTO, CANADA – September 4, 2025 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that George Tzira |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 3, 2025 |
Cybin to Participate in the Cantor Global Healthcare Conference 2025 Cybin to Participate in the Cantor Global Healthcare Conference 2025 TORONTO, CANADA – September 3, 2025 – Cybin Inc. |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 2, 2025 |
Cybin Announces Senior Leadership Changes Doug Drysdale to step down as Chief Executive Officer; Eric So appointed Interim Chief Executive Officer This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated February 10, 2025, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023, April 8, 2024, and January 6, 2025. |
|
| August 26, 2025 |
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - EMBRACE, the second study within the CYB003 Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia - - Recently cleared to initiate the EMBRACE study in Ireland, |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 19, 2025 |
REPORT OF VOTING RESULTS SECTION 11.3 OF NATIONAL INSTRUMENT 51-102 REPORT OF VOTING RESULTS SECTION 11.3 OF NATIONAL INSTRUMENT 51-102 In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the annual meeting of the holders of the common shares (the “Shareholders”) of Cybin Inc. (“Cybin”) held on August 18, 2025 (the “Meeting”). There were 90 Shareholders re |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 19, 2025 |
Cybin Announces Results of Annual Meeting of Shareholders Cybin Announces Results of Annual Meeting of Shareholders TORONTO, CANADA – August 18, 2025 – Cybin Inc. |
|
| August 14, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 14, 2025 |
CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025 CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. ("Cybin") have been prepared by and are the responsibility of Cybin's management in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting as issued by the Intern |
|
| August 14, 2025 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three months ended June 30, 2025 Date: August 13, 2025 CYBIN INC. MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s unaudited condensed i |
|
| August 14, 2025 |
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results Cybin continues to make significant progress on its journey to bring breakthrough therapy to patients by delivering on the following key milestones - Received European and United Kingdom Medical and Healthcare Products Regulatory Agency (“MHRA”) approval for EMBRACE, the Company’s second pivotal |
|
| August 14, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Douglas Drysdale, as Chief Executive Officer of Cybin Inc. |
|
| August 13, 2025 |
CYBIN INC. Amended and Restated Convertible Note THE SECURITIES REPRESENTED HEREBY AND THOSE SECURITIES INTO WHICH THEY ARE CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. |
|
| August 13, 2025 |
OMNIBUS AMENDMENT This Omnibus Amendment (this “Amendment”), dated as of August 12, 2025, is by and between CYBIN INC. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 7, 2025 |
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - EMBRACE, the second study within the Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe, the United Kingdom, and Australia - - European CTA approval to initiate the EMBRACE s |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 6, 2025 |
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference TORONTO, CANADA – August 6, 2025 – Cybin Inc. |
|
| July 31, 2025 |
CYBIN INC. as Issuer and [ ] as U.S. Trustee and [ ] as Canadian Trustee Indenture Dated as of [ ] TABLE OF CONTENTS ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.01 Definitions 1 SECTION 1.02 Rules of Construction 9 SECTION 1.03 Compliance Certificates and Opinions 10 SECTION 1.04 Form of Documents Delivered to Trustees 10 SECTION 1.05 Acts of Holders 11 SECTION |
|
| July 31, 2025 |
As filed with the Securities and Exchange Commission on July 31, 2025. As filed with the Securities and Exchange Commission on July 31, 2025. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYBIN INC. (Exact name of Registrant as specified in its charter) Ontario, Canada (Province or other jurisdiction of incorporation or organization) 2834 (Primary Standard Ind |
|
| July 31, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables F-10 CYBIN INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule or Instruction Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Other Common Shares, Warrants, Units, Debt Securities Subscription Receipts 457(o) Fees to be Paid 1 Unallocated (U |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing ("Filer"): Cybin Inc. B. (1) This is [check one]: ☒ an original filing for the Filer ☐ an amended filing for the Filer (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rul |
|
| July 28, 2025 |
CYBIN INC. (the “Corporation”) ABRIDGEMENT CERTIFICATE Pursuant to Section 2.20 of National Instrument 54-101 Reference is made to the annual and special meeting of the shareholders (the “Meeting”) of the Corporation scheduled to be held on August 18, 2025. I, Douglas Drysdale, as the duly appointed Chief Executive Officer of the Corporation, hereby certify on behalf of the Corporation and not in |
|
| July 28, 2025 |
CYBIN INC. (the “Corporation”) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS CYBIN INC. (the “Corporation”) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that an annual general meeting (the “Meeting”) of the holders (collectively, the “Shareholders” or individually, a “Shareholder”) of the common shares in the capital of the Corporation (the “Common Shares”) will be held on August 18, 2025 at the hour of 10:00 a.m. (Toronto time). The Meeting will |
|
| July 28, 2025 |
Cybin Inc. Form of Proxy – Annual General Meeting to be held on August 18, 2025 Trader’s Bank Building 702, 67 Yonge Street Toronto ON M5E 1J8 Appointment of Proxyholder I/We being the undersigned holder(s) of Cybin Inc. hereby appoint Eric So, Chair and President or failing this person, Gabriel Fahel, Chief Legal Officer (the “Management Nominees”) OR Print the name of the person you are appointi |
|
| July 28, 2025 |
CYBIN INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS CYBIN INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR July 14, 2025 TABLE OF CONTENTS NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - 2 - MANAGEMENT INFORMATION CIRCULAR - 4 - SOLICITATION OF PROXIES - 4 - VOTING AT THE MEETING - 4 - APPOINTMENT AND REVOCATION OF PROXIES - 5 - EXERCISE OF DISCRETION BY PROXIES - 5 - HOW DO I ATTEND AND PARTICIPATE AT TH |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 17, 2025 |
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia and will commence imminently - - PARADIGMTM comprises two 1 |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 14, 2025 |
Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-284173 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated August 17, 2023, as amended by Amendment No. 1 dated December 22, 2023, by Amendment No. 2 dated April 8, 2024, and by Amendment No. 3 dated January 6, 2025, to which it relates, as amended or supplemented (th |
|
| July 14, 2025 |
July 14, 2025 VIA EDGAR Cybin Inc. 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Dear Sirs/Mesdames: Re: Cybin Inc. (the "Company") - Prospectus Supplement dated July 14, 2025 to the Short Form Base Shelf Prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025 (the "Prospectus Supplement") We hereby consent to the reference to our firm name |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 10, 2025 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc. (the “Company”) 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material Change June 30, 2025 Item 3. News Release A news release with respect to the material change was disseminated by the Company on June 30, 2025 through Business Wire. Item 4. Summary of Material Change On June 30, 2025, |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 1, 2025 |
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights - Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients1 - - Strengthened commercial preparations and |
|
| July 1, 2025 |
Exhibit 99.5 CERTIFICATION I, Greg Cavers, certify that: 1. I have reviewed this annual report on Form 40-F of Cybin Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period |
|
| July 1, 2025 |
To the United States Securities and Exchange Commission To the United States Securities and Exchange Commission We consent to the incorporation by reference in the Annual Report on Form 40-F of Cybin Inc. |
|
| July 1, 2025 |
Exhibit 99.4 CERTIFICATION I, Doug Drysdale, certify that: 1. I have reviewed this annual report on Form 40-F of Cybin Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the peri |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 1, 2025 |
CYBIN ANNOUNCES FINANCING OF UP TO US$500 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE DEBENTURES - Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 - TORONTO – June 30, 2025 - Cybin Inc. |
|
| July 1, 2025 |
SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”), dated as of June 30, 2025, is between CYBIN INC. |
|
| July 1, 2025 |
CYBIN INC. Consolidated Financial Statements MARCH 31, 2025 AND 2024 CYBIN INC. Consolidated Financial Statements MARCH 31, 2025 AND 2024 Responsibility for Consolidated Financial Statements The Company’s management is responsible for the integrity and fairness of presentation of these consolidated financial statements. The consolidated financial statements have been prepared by management, in accordance with International Financial Reporting Standards as issued by |
|
| July 1, 2025 |
Exhibit 99.7 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Cybin Inc. (the “Company”) on Form 40-F for the period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Greg Cavers, Chief Financial Officer of the Company, certify, pursua |
|
| July 1, 2025 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the year ended March 31, 2025 Date: June 30, 2025 CYBIN INC. MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s audited consolidated financial |
|
| July 1, 2025 |
SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”), dated as of June 30, 2025, is between CYBIN INC. |
|
| July 1, 2025 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 30, 2025 is made by and between High Trail Special Situations LLC , a High Trail Special Situations LLC, 290 Harbor Drive, 3rd Floor Stamford, CT 06902 Attn: Capital Solutions (the “Investor”), and Cybin Inc. |
|
| July 1, 2025 |
Cybin Inc. INCENTIVE COMPENSATION RECOVERY POLICY August 2023 CYBIN INC. INCENTIVE COMPENSATION RECOVERY POLICY 1.Introduction. The Board of Directors of Cybin Inc. (the “Company”) believe that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The B |
|
| July 1, 2025 |
Exhibit 99.6 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Cybin Inc. (the “Company”) on Form 40-F for the period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Doug Drysdale, Chief Executive Officer of the Company, certify, purs |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F [ ] Registration statement pursuant to Section 12 of the Securities Exchange Act of 1934 or [X] Annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended March 31, 2025 Commission File Number 001-40673 Cybin Inc. (Exact name of Registrant as specified in its cha |
|
| July 1, 2025 |
CYBIN INC. ANNUAL INFORMATION FORM FOR THE YEAR ENDED MARCH 31, 2025 JUNE 30, 2025 CYBIN INC. ANNUAL INFORMATION FORM FOR THE YEAR ENDED MARCH 31, 2025 JUNE 30, 2025 TABLE OF CONTENTS Page GENERAL 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 1 MARKET AND INDUSTRY DATA 5 REGULATORY 5 GLOSSARY OF TERMS 6 CORPORATE STRUCTURE 14 GENERAL DEVELOPMENT OF THE BUSINESS 16 DESCRIPTION OF THE BUSINESS 27 RISK FACTORS 76 DIVIDEND AND DISTRIBUTIONS 110 DESCRIPTION OF CAPITAL STRUCT |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| June 13, 2025 |
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder (“MDD”) with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) - - Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company’s commercialization and manufacturing capabilities - - Positive regulatory signals from U. |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| June 12, 2025 |
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference TORONTO, CANADA – June 12, 2025 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drys |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| June 11, 2025 |
Cybin to Participate in the 2025 Psychedelic Science Conference - Cybin CEO Doug Drysdale to participate in a panel discussion titled “The Home Stretch: Pivotal Trials and Preparing for Launch” on June 19, 2025 - TORONTO, CANADA – June 11, 2025 – Cybin Inc. |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| June 3, 2025 |
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder - Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine (“DMT”) and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 - - Cybin’s growing intellectual property portfolio comprises more t |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 22, 2025 |
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 TORONTO, CANADA – May 22, 2025 – Cybin Inc. |
|
| May 20, 2025 |
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - U.S. Food and Drug Administration (“FDA”) Commissioner identifies psychedelic drug development as a top agency priority in an effort to address unmet needs in mental health - - Calls for FDA to be open to innovative treatments that show promise, even when they challenge trad |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 15, 2025 |
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Thermo Fisher Scientific, the world leader in serving science, is providing Phase 3 capsule clinical supply and will support future commercial manufacturing efforts for CYB003 - - Production of both drug substance and drug product will be per |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 14, 2025 |
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase TORONTO, CANADA – May 14, 2025 – Cybin Inc. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 8, 2025 |
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - Newly issued patent includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041 - - Cybin’s growing intellectual property portfolio comprises more than 80 granted patents and over 230 pending a |
|
| May 1, 2025 |
Cybin to Participate at the 28th Annual Milken Institute Global Conference - Doug Drysdale, CEO, to appear on panel entitled “The Global Landscape and Opportunities for Medical Breakthroughs,” on May 5, 2025 - TORONTO, CANADA – May 1, 2025 – Cybin Inc. |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| April 23, 2025 |
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 21, 2025 |
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline - - Osmind is a leading service provider to psychiatry practices in the U. |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110258.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State |
|
| February 14, 2025 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc. (the "Company") 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material Change February 10, 2025 Item 3. News Release A news release disclosing the material change was disseminated by the Company on February 10, 2025 through BusinessWire. Item 4. Summary of Material Change On February 10, |
|
| February 11, 2025 |
February 10, 2025 VIA EDGAR Cybin Inc. 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Dear Sirs/Mesdames: Re: Cybin Inc. (the "Company") Prospectus Supplement dated February 10, 2025 to the Short Form Base Shelf Prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025 (the "Prospectus Supplement") We hereby consent to the reference to our firm |
|
| February 11, 2025 |
CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. ("Cybin") have been prepared by and are the responsibility of Cybin's management in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting as issued by the In |
|
| February 11, 2025 |
SUPPL 1 formsuppl.htm FORM SUPPL Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-284173 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated August 17, 2023, as amended by Amendment No. 1 dated December 22, 2023, by Amendment No. 2 dated April 8, 2024, and by Amendment No. 3 dated January 6, 2025, to which it relate |
|
| February 11, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 11, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Douglas Drysdale, as Chief Executive Officer of Cybin Inc. |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 11, 2025 |
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights - Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder (“MDD”) - - PARADIGM comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE |
|
| February 11, 2025 |
Cybin Inc. Shares of Common Stock EQUITY DISTRIBUTION AGREEMENT Cybin Inc. Shares of Common Stock EQUITY DISTRIBUTION AGREEMENT February 10, 2025 Cantor Fitzgerald Canada Corporation 181 University Avenue, Suite 1500 Toronto, Ontario M5H 3M7 Cantor Fitzgerald & Co. 110 East 59th St, 6th Floor New York, NY 10022 Ladies and Gentlemen: Cybin Inc., a company continued under the Business Corporations Act (Ontario) ("Cybin" or the "Company"), confirms its agreement |
|
| February 11, 2025 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three and nine months ended December 31, 2024 Date: February 10, 2025 CYBIN INC. MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s unaudi |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| January 15, 2025 |
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance - - First program member is Segal Trials, a preferred provider for leading pharmaceutical companies globally - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of patients - TORONTO, CANADA – January 15, 2025 – Cybin Inc. |
|
| January 13, 2025 |
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 - Announced positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder (“MDD”) - - Initiated PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of MDD – - Received U. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| January 10, 2025 |
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 EX-99.1 2 a01-09x2025lythamhealthcar.htm EX-99.1 Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 TORONTO, CANADA – January 9, 2025 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-gener |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| January 8, 2025 |
EX-FILING FEES Calculation of Filing Fee Tables FORM F-10 (Form Type) CYBIN INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(3) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration |
|
| January 8, 2025 |
CYBIN INC. as Issuer and [ ] as U.S. Trustee and [ ] as Canadian Trustee Indenture Dated as of [ ] TABLE OF CONTENTS ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.01 Definitions 1 SECTION 1.02 Rules of Construction 9 SECTION 1.03 Compliance Certificates and Opinions 10 SECTION 1.04 Form of Documents Delivered to Trustees 10 SECTION 1.05 Acts of Holders 11 SECTION |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing ("Filer"): Cybin Inc. B. (1) This is [check one]: ☒ an original filing for the Filer ☐ an amended filing for the Filer (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rul |
|
| January 8, 2025 |
As filed with the Securities and Exchange Commission on January 7, 2025. As filed with the Securities and Exchange Commission on January 7, 2025. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYBIN INC. (Exact name of Registrant as specified in its charter) Ontario, Canada (Province or other jurisdiction of incorporation or organization) 2834 (Primary Standard I |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| December 10, 2024 |
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results - Poster presentations highlight clinical data across Cybin’s CYB003 deuterated psilocin and DMT programs - TORONTO, CANADA – December 10, 2024 – Cybin Inc. |
|
| December 4, 2024 |
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 TORONTO, CANADA – December 4, 2024 – Cybin Inc. |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| December 3, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Shares, no par value, of Cybin Inc. and further agree to the filing of this agreement as an exhib |
|
| December 3, 2024 |
CYBN / Cybin Inc. / TANG CAPITAL MANAGEMENT LLC Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 18, 2024 |
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared |
|
| November 14, 2024 |
CYBN / Cybin Inc. / Logos Global Management LP Passive Investment SC 13G/A 1 cybn13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Cybin Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 23256X100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| November 14, 2024 |
CYBN / Cybin Inc. / Point72 Asset Management, L.P. - CYBIN INC. Passive Investment SC 13G/A 1 p24-3230sc13ga.htm CYBIN INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cybin Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 23256X407 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 14, 2024 |
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - Company to host conference call and webcast at 8:00 a. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 13, 2024 |
CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. ("Cybin") have been prepared by and are the responsibility of Cybin's management in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting as issued by the I |
|
| November 13, 2024 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three and six months ended September 30, 2024 Date: November 12, 2024 CYBIN INC. MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s unaudi |
|
| November 13, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 13, 2024 |
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - PARADIGM TM program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - APPROACH TM: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans with Major Depressive Disorder has been initiated and will enroll 220 patients at 36 clinical sites across the U. |
|
| November 13, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Douglas Drysdale, as Chief Executive Officer of Cybin Inc. |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| November 1, 2024 |
Cybin to Participate at the 2024 Milken Institute Future of Health Summit - CEO Doug Drysdale to speak on panel about novel approaches to mental health treatments on November 13, 2024 - TORONTO, CANADA – October 31, 2024 – Cybin Inc. |
|
| October 24, 2024 |
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program - The Company is evaluating non-hallucinogenic dosing of CYB005 preclinical candidate molecules for the treatment of CNS disorders - - Cybin’s sector-leading intellectual property portfolio now includes over 70 granted patents and more than 220 patent applications pending - TORONTO, CA |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| October 3, 2024 |
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 TORONTO, CANADA – October 3, 2024 – Cybin Inc. |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| October 1, 2024 |
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program - Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder (“MDD”) imminently - - Cybin welcomes Dr. |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| September 24, 2024 |
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit TORONTO, CANADA – September 24, 2024 – Cybin Inc. |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 20, 2024 |
Cybin Provides Corporate Update on Upcoming Clinical Milestones - Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder (“MDD”) expected imminently - - 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 - - Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxiety Disorder (“GAD”) expected year-end 2024 or early Q1 2025 - - Strengthened R&D team with addition of experienced drug development leaders Dr. |
|
| September 20, 2024 |
Cybin Announces Completion of Previously Announced Share Consolidation Cybin Announces Completion of Previously Announced Share Consolidation TORONTO, CANADA – September 19, 2024 – Cybin Inc. |
|
| September 20, 2024 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Cybin Inc. |
|
| September 20, 2024 |
CYBIN INC LETTER OF TRANSMITTAL CYBIN INC LETTER OF TRANSMITTAL TO: ODYSSEY TRUST COMPANY The undersigned hereby represents and warrants that the undersigned is the owner of the number of common shares (“common shares”) of Cybin Inc. |
|
| September 20, 2024 |
certificateandarticlesof Ministry of Public and Business Service Delivery Ministère des Services au public et aux entreprises Certificate of Amendment Certificat de modification Business Corporations Act Loi sur les sociétés par actions CYBIN INC. |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principa |
|
| September 4, 2024 |
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference TORONTO, CANADA – September 4, 2024 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 29, 2024 |
REPORT OF VOTING RESULTS SECTION 11.3 OF NATIONAL INSTRUMENT 51-102 REPORT OF VOTING RESULTS SECTION 11.3 OF NATIONAL INSTRUMENT 51-102 In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the annual and special meeting of the holders of the common shares (the “Shareholders”) of Cybin Inc. (“Cybin”) held on August 27, 2024 (the “Meeting”). There were 87 Sha |
|
| August 28, 2024 |
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation TORONTO, CANADA – August 27, 2024 – Cybin Inc. |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 27, 2024 |
CYBN / Cybin Inc. / Logos Global Management LP Passive Investment SC 13G 1 cybn13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Cybin Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 23256X100 (CUSIP Number) March 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| August 19, 2024 |
CYBIN INC. (the “Corporation”) NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS CYBIN INC. (the “Corporation”) NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that an annual and special meeting (the “Meeting”) of the holders (collectively, the “Shareholders” or individually, a “Shareholder”) of the common shares in the capital of the Corporation (the “Common Shares”) will be held on August 27, 2024 at the hour of 10:00 a.m. (Toronto time). The Meet |
|
| August 19, 2024 |
CYBIN INC. (the “Corporation”) ABRIDGEMENT CERTIFICATE Pursuant to Section 2.20 of National Instrument 54-101 Reference is made to the annual and special meeting of the shareholders (the “Meeting”) of the Corporation scheduled to be held on August 27, 2024. I, Douglas Drysdale, as the duly appointed Chief Executive Officer of the Corporation, hereby certify on behalf of the Corporation and not in |
|
| August 19, 2024 |
CYBIN INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS CYBIN INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR July 24, 2024 TABLE OF CONTENTS MANAGEMENT INFORMATION CIRCULAR 4 SOLICITATION OF PROXIES 4 VOTING AT THE MEETING 4 APPOINTMENT AND REVOCATION OF PROXIES 5 EXERCISE OF DISCRETION BY PROXIES 5 HOW DO I ATTEND AND PARTICIPATE AT THE MEETING? 6 ADVICE TO BENEFICIAL SHAREHOLDERS 6 NOTE TO NON-OBJECTING |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Addre |
|
| August 19, 2024 |
CYBIN INC. Form of Proxy – Annual and Special Meeting to be held on August 27, 2024 Trader’s Bank Building 702, 67 Yonge Street Toronto ON M5E 1J8 Appointment of Proxyholder I/We being the undersigned holder(s) of common shares of Cybin Inc. (the “Corporation”) hereby appoint Eric So, Chair and President, or failing this person, Gabriel Fahel, Chief Legal Officer (the “Management Nominees”) OR Pri |
|
| August 15, 2024 |
CYBIN INC. (the “Corporation”) ABRIDGEMENT CERTIFICATE Pursuant to Section 2.20 of National Instrument 54-101 Reference is made to the annual and special meeting of the shareholders (the “Meeting”) of the Corporation scheduled to be held on August 27, 2024. I, Douglas Drysdale, as the duly appointed Chief Executive Officer of the Corporation, hereby certify on behalf of the Corporation and not in |
|
| August 15, 2024 |
CYBIN INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS CYBIN INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR July 24, 2024 TABLE OF CONTENTS MANAGEMENT INFORMATION CIRCULAR 4 SOLICITATION OF PROXIES 4 VOTING AT THE MEETING 4 APPOINTMENT AND REVOCATION OF PROXIES 5 EXERCISE OF DISCRETION BY PROXIES 5 HOW DO I ATTEND AND PARTICIPATE AT THE MEETING? 6 ADVICE TO BENEFICIAL SHAREHOLDERS 6 NOTE TO NON-OBJECTING |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 13, 2024 |
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder - Company expects to initiate Phase 3 pivotal trial in late summer 2024 - - Phase 3 pivotal study to include 30 clinical sites across the United States and Europe with deep expertise in depression studies - - Pivotal trial designs incorporate elements to address functional unblinding - - Company to report 12-month Phase 2 efficacy data for CYB003 in Major Depressive Disorder (“MDD”) in Q4 2024 - TORONTO, CANADA – August 13, 2024 – Cybin Inc. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| August 8, 2024 |
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights - Phase 3 multinational study of CYB003 expected to begin in late summer 2024 - - 30 clinical sites selected across the United States and Europe for Phase 3 CYB003 study - - 12-month efficacy results from Phase 2 study of CYB003 in MDD expected Q4 2024 - - Additional United States patent granted providing |
|
| August 8, 2024 |
CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. ("Cybin") have been prepared by and are the responsibility of Cybin's management in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting as issued by the Intern |
|
| August 8, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| August 8, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Douglas Drysdale, as Chief Executive Officer of Cybin Inc. |
|
| August 8, 2024 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three months ended June 30, 2024 Date: August 7, 2024 CYBIN INC. MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s unaudited condensed in |
|
| August 7, 2024 |
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference TORONTO, CANADA – August 7, 2024 – Cybin Inc. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| July 5, 2024 |
July 3, 2024 REVISED Filed via SEDAR+ To All Applicable Exchanges and Securities Administrators Subject: Cybin Inc. |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Addres |
|
| June 27, 2024 |
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights - Received U. |
|
| June 26, 2024 |
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights - Received U. |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F [ ] Registration statement pursuant to Section 12 of the Securities Exchange Act of 1934 or [X] Annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended March 31, 2024 Commission File Number 001-40673 Cybin Inc. (Exact name of Registrant as specified in its cha |
|
| June 26, 2024 |
CYBIN INC. CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 AND 2023 CYBIN INC. CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 AND 2023 Responsibility for Consolidated Financial Statements The Company’s management is responsible for the integrity and fairness of presentation of these consolidated financial statements. The consolidated financial statements have been prepared by management, in accordance with International Financial Reporting Standards as issued by |
|
| June 26, 2024 |
INCENTIVE COMPENSATION RECOVERY POLICY Cybin Inc. INCENTIVE COMPENSATION RECOVERY POLICY August 2023 CYBIN INC. INCENTIVE COMPENSATION RECOVERY POLICY 1.Introduction. The Board of Directors of Cybin Inc. (the “Company”) believe that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The B |
|
| June 26, 2024 |
FORM 52-109F1 Certification of Annual Filings Full Certificate FORM 52-109F1 Certification of Annual Filings Full Certificate I, Douglas Drysdale, Chief Executive Officer of Cybin Inc. |
|
| June 26, 2024 |
FORM 52-109F1 Certification of Annual Filings Full Certificate FORM 52-109F1 Certification of Annual Filings Full Certificate I, Greg Cavers, Chief Financial Officer of Cybin Inc. |
|
| June 26, 2024 |
CYBIN INC. ANNUAL INFORMATION FORM FOR THE YEAR ENDED MARCH 31, 2024 JUNE 25, 2024 CYBIN INC. ANNUAL INFORMATION FORM FOR THE YEAR ENDED MARCH 31, 2024 JUNE 25, 2024 TABLE OF CONTENTS Page GENERAL 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 1 MARKET AND INDUSTRY DATA 5 REGULATORY 5 GLOSSARY OF TERMS 7 CORPORATE STRUCTURE 15 GENERAL DEVELOPMENT OF THE BUSINESS 17 DESCRIPTION OF THE BUSINESS 30 RISK FACTORS 78 DIVIDEND AND DISTRIBUTIONS 112 DESCRIPTION OF CAPITAL STRUCT |
|
| June 26, 2024 |
To the United States Securities and Exchange Commission To the United States Securities and Exchange Commission We consent to the incorporation by reference in the Annual Report on Form 40-F of Cybin Inc. |
|
| June 26, 2024 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the year ended March 31, 2024 Date: June 25, 2024 CYBIN INC. Management’s Discussion and Analysis This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s audited consolidated financial |
|
| June 26, 2024 |
Cybin Inc. Consolidated Financial Statements March 31, 2024 and 2023 Responsibility for Consolidated Financial Statements The Company’s management is responsible for the integrity and fairness of presentation of these consolidated financial statements. The consolidated financial statements have been prepared by management, in accordance with International Financial Reporting Standards as issued by |
|
| June 26, 2024 |
Exhibit 99.7 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Cybin Inc. (the “Company”) on Form 40-F for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Greg Cavers, Chief Financial Officer of the Company, certify, pursua |
|
| June 26, 2024 |
Exhibit 99.6 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Cybin Inc. (the “Company”) on Form 40-F for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Doug Drysdale, Chief Executive Officer of the Company, certify, purs |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March , 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal e |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| June 20, 2024 |
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference TORONTO, CANADA – June 19, 2024 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exe |
|
| June 11, 2024 |
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development - Dr. Mahableshwarkar, a Board-Certified Psychiatrist, is an experienced pharmaceutical industry leader with decades of expertise in drug development - TORONTO, CANADA – June 11, 2024 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company com |
|
| May 29, 2024 |
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 - Amir Inamdar, Chief Medical Officer, to appear on panel discussions on June 5 and June 8 - - Ellen James, Director, Clinical Development, to present abstract titled “SPL026 (DMT fumarate) in combination with SSRIs for patients with Major Depressive Disorder” on June 6, 2024 - TORONTO, CANADA – May 29, 2024 – Cybin Inc. |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 14, 2024 |
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase TORONTO, CANADA – May 14, 2024 – Cybin Inc. |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal exec |
|
| May 6, 2024 |
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones - Recent U. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 25, 2024 |
Cybin to Participate at the 27th Annual Milken Institute Global Conference - Doug Drysdale, CEO, to appear on panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024 - TORONTO, CANADA – April 25, 2024 – Cybin Inc. |
|
| April 18, 2024 |
Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-276333 This prospectus supplement (the "Prospectus Supplement"), together with the short form base shelf prospectus dated August 17, 2023, as amended pursuant to amendment no. 1 to the short form base shelf prospectus dated December 22, 2023, to which it relates, and as amended pursuant to amendment no. 2 to the short form base s |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 18, 2024 |
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry - Publication explores structure-activity relationships (“SAR”) of a broad range of 2C-X analogs - - Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist with favorable pharmacokinetic properties - TORONTO, CANADA – April 18, 2024 – Cybin Inc. |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 18, 2024 |
April 18, 2024 VIA EDGAR Cybin Inc. 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Dear Sirs/Mesdames: Re: Cybin Inc. (the "Company") - Prospectus Supplement dated April 17, 2024 to the Short Form Base Shelf Prospectus dated August 17, 2023, as amended on December 22, 2023 and April 8, 2024 (the "Prospectus Supplement") We hereby consent to the reference to our firm name on page S-5 of |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 16, 2024 |
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder - Newly issued patent expected to provide exclusivity until at least 2041 and includes claims to pharmaceutical compositions within the Company’s proprietary deuterated psilocybin analog program - - Cybin’s patent portfolio now includes more than 50 granted patents an |
|
| April 11, 2024 |
As filed with the Securities and Exchange Commission on April 10, 2024. As filed with the Securities and Exchange Commission on April 10, 2024. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYBIN INC. (Exact name of Registrant as specified in its charter) Ontario, Canada (Province or other jurisdiction of incorporation or organ |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| April 10, 2024 |
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference TORONTO, CANADA – April 10, 2024– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, |
|
| March 25, 2024 |
CYBN / Cybin Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm249699d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cybin Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 23256X100 (CUSIP Number) March 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| March 22, 2024 |
CYBN / Cybin Inc. / Deep Track Capital, LP Passive Investment SC 13G 1 deeptrack-cybn031424.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cybin Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 23256X100 (CUSIP Number) March 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| March 22, 2024 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc. (the "Company") 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material Change March 13, 2024 Item 3. News Release News releases with respect to the material change were disseminated by the Company on March 13 and March 19, 2024 through BusinessWire. Item 4. Summary of Material Change On |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| March 21, 2024 |
AGENCY AGREEMENT March 19, 2024 CYBIN INC. 100 King St West Suite 5600 Toronto, ON M5X 1C9 Attention: Doug Drysdale, Chief Executive Officer Dear Sir: Bloom Burton Securities Inc. (the "Lead Agent") and Haywood Securities Inc. (together with the Lead Agent, the "Agents") understand that Cybin Inc. (the "Corporation") proposes to issue and/or sell, as applicable, on a "commercially reasonable effor |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| March 20, 2024 |
Announces Oversubscribed Private Placement of U.S. $150 Million Announces Oversubscribed Private Placement of U.S. $150 Million THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, CANADA – March 13, 2024 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company commit |
|
| March 20, 2024 |
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, CANADA – March 19, 2024 – Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmace |
|
| March 18, 2024 |
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas TORONTO, CANADA – March 18, 2024 – Cybin Inc. |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| March 15, 2024 |
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder - Anxiety disorders are the most prevalent mental health disorders globally1, contributing to over 28 million disability-adjusted life years (“DALYs”)2 - - Highly scalable intermittent treatment for Generalized Anxiety Disorder (“GAD”) with an expected treatment time of approximately 90-minutes from a single administration - - Proprietary deuterated dimethyltryptamine (“DMT”) molecule with U. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| March 14, 2024 |
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design - With U. |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| March 13, 2024 |
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder - Breakthrough Therapy Designation (“BTD”) provides an expedited review pathway, as well as increased access to U. |
|
| March 13, 2024 |
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 - Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (“MDD”) - - Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer - TORONTO, CANADA – March 12, 2024 – Cybin Inc. |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal ex |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 27, 2024 |
Cybin to Present at the TD Cowen 44th Annual Health Care Conference Cybin to Present at the TD Cowen 44th Annual Health Care Conference TORONTO, CANADA – February 27, 2024 – Cybin Inc. |
|
| February 15, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| February 15, 2024 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three and nine months ended December 31, 2023 Date: February 13, 2024 CYBIN INC. Management’s Discussion and Analysis This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s interi |
|
| February 15, 2024 |
Cybin Reports Third Quarter Financial Results and Recent Business Highlights - Reported positive Phase 2 topline results for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”), demonstrating a 79% remission rate from depression - - Announced positive topline results from Phase 1 studies of proprietary deuterated dimethyltryptamine (“dDMT”) molecules CYB004 and SPL028, supporting clinical advancement and the successful development of an intramuscular (“IM”) formulation - - Received clearance from U. |
|
| February 15, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Douglas Drysdale, as Chief Executive Officer of Cybin Inc. |
|
| February 15, 2024 |
CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. ("Cybin") have been prepared by and are the responsibility of Cybin's management in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting as issued by the In |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Add |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 14, 2024 |
Cybin Inc. Management’s Discussion and Analysis of Financial Condition and Operating Performance For the three and nine months ended December 31, 2023 Date: February 13, 2024 CYBIN INC. Management’s Discussion and Analysis This Management’s Discussion and Analysis (“MD&A”) has been prepared by management of Cybin Inc. (“Cybin” or the “Company”) and should be read in conjunction with Cybin’s interi |
|
| February 14, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Greg Cavers, as Chief Financial Officer of Cybin Inc. |
|
| February 14, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Douglas Drysdale, as Chief Executive Officer of Cybin Inc. |
|
| February 14, 2024 |
CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 CYBIN INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 (UNAUDITED) TO OUR SHAREHOLDERS The accompanying unaudited condensed interim consolidated financial statements of Cybin Inc. ("Cybin") have been prepared by and are the responsibility of Cybin's management in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting as issued by the In |
|
| February 14, 2024 |
Cybin Reports Third Quarter Financial Results and Recent Business Highlights - Reported positive Phase 2 topline results for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”), demonstrating a 79% remission rate from depression - - Announced positive topline results from Phase 1 studies of proprietary deuterated dimethyltryptamine (“dDMT”) molecules CYB004 and SPL028, supporting clinical advancement and the successful development of an intramuscular (“IM”) formulation - - Received clearance from U. |
|
| February 14, 2024 |
CYBN / Cybin Inc. / Point72 Asset Management, L.P. - CYBIN INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cybin Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 23256X100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| February 7, 2024 |
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program - Newly issued patents include protection for injectable formulations and synthesis methods for the preparation of dimethyltryptamine (“DMT”) and deuterated DMT (“dDMT”) - - Patent protection further strengthens intellectual property portfolio in the 3rd largest pharmaceutical market globally - - Cybin’s patent portfolio now includes 51 granted patents and over 170 pending applications - TORONTO, CANADA – February 7, 2024 – Cybin Inc. |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| January 23, 2024 |
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder - Recently announced positive Phase 1 topline safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data show that intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT - - U. |
|
| January 8, 2024 |
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028 - Intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment - - Intramuscular (“IM”) dosing of SPL028 produced robust, short-duration psychedelic effects in the |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
|
| January 4, 2024 |
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs - Recently announced positive Phase 2 topline data in Major Depressive Disorder (“MDD”) with 79% of patients in remission from depression after two doses of CYB003 (12mg) - - Programs supported by robust intellectual property portfolio with 40 granted patents and over 170 pending applications - - Multinational operations support scaling to Phase 3 trial of CYB003 in MDD and Phase 2 study of deuterated dimethyltryptamine (“dDMT”) in Generalized Anxiety Disorder (“GAD”) in early 2024 - - Phase 1 deuterated DMT readouts (CYB004/SPL028) in final analysis - TORONTO, CANADA – January 4, 2024 – Cybin Inc. |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing ("Filer"): Cybin Inc. B. (1) This is [check one]: ☒ an original filing for the Filer ☐ an amended filing for the Filer (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rul |
|
| December 29, 2023 |
CYBIN INC. as Issuer and [ ] as U.S. Trustee and [ ] as Canadian Trustee Indenture Dated as of [ ] TABLE OF CONTENTS ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.01 Definitions 1 SECTION 1.02 Rules of Construction 9 SECTION 1.03 Compliance Certificates and Opinions 10 SECTION 1.04 Form of Documents Delivered to Trustees 10 SECTION 1.05 Acts of Holders 11 SECTION |
|
| December 29, 2023 |
As filed with the Securities and Exchange Commission on December 29, 2023. As filed with the Securities and Exchange Commission on December 29, 2023. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYBIN INC. (Exact name of Registrant as specified in its charter) Ontario, Canada (Province or other jurisdiction of incorporation or organization) 2834 (Primary Standard |
|
| December 29, 2023 |
EX-FILING FEES Calculation of Filing Fee Tables FORM F-10 (Form Type) CYBIN INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(3) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023. Commission File Number: 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal |
